08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Bradykinin B1 receptor (BDKRB1; B1R)-targeting PET imaging agent

Imaging TECHNOLOGY: PET A radiolabeled B1R-targeting peptide could be useful as a tumor-targeted PET imaging agent. The agent consisted of a B1R-targeting 10-mer kallidin peptide analog that incorporated non-natural amino acids conjugated to the positron-emitting radionuclide 68Ga....
08:00 , Nov 5, 2012 |  BC Week In Review  |  Clinical News

FOV2304: Development discontinued

Sanofi disclosed in its 3Q12 earnings that it discontinued development of FOV2304 to treat DME. FOV2304 was in Phase II testing for the indication. The pharma declined to disclose details. Sanofi gained the product from...
07:00 , May 17, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Bradykinin B1 receptor (BDKRB1; B1R) An in vitro and mouse study...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Genesis Biopharma, SciMeDent Health Corp. deal

SciMeDent (formerly Trend Exploration Inc.) and Genesis mutually terminated a proposed deal granting SciMeDent exclusive, worldwide rights to R-954 to treat painful diabetic neuropathy after SciMeDent was unable to acquire sufficient capital to finance the...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Genesis Biopharma, SciMeDent Health Corp. deal

The companies signed a binding letter of intent under which Genesis will grant SciMeDent (formerly Trend Exploration Inc.) exclusive, worldwide rights to R-954 to treat painful diabetic neuropathy. Genesis has received permission from Health Canada...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

Fovea Pharmaceuticals, Merrimack, sanofi-aventis deal

sanofi-aventis will acquire Fovea for €90 million ($131.5 million) up front and up to € 280 million ($409 million) in milestones related to ophthalmic compounds FOV1101, FOV2302 and FOV2304. The most advanced compound is...
07:00 , Jul 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Inflammatory disease; multiple sclerosis (MS) ...